Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms

Endocrine

Volumn 47, Issue 2, 2014, Pages 581-589

  Procopio, M ^a   Barale, M ^a   Bertaina, S ^a   Sigrist, S ^a   Mazzetti, R ^a   Loiacono, M ^b   Mengozzi, G ^b   Ghigo, E ^a   Maccario, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Cardiovascular; Hyperparathyroidism; Metabolic syndrome

Indexed keywords

CALCIUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ARTICLE; ASYMPTOMATIC DISEASE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GENDER; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY HYPERPARATHYROIDISM; RISK FACTOR; SYMPTOMATOLOGY; AGED; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPLICATION; METABOLISM; MIDDLE AGED;

AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 84911005904     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0091-z     Document Type: Article

References (38)

1. S.J. Silverberg, E.M. Lewiecki, L. Mosekilde, M. Peacock, M.R. Rubin, Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94, 351–365 (2009)
2. I.L. Nilsson, L. Yin, E. Lundgren, J. Rastad, A. Ekbom, Clinical presentation of primary hyperparathyroidism in Europe–nationwide cohort analysis on mortality from nonmalignant causes. J. Bone Miner. Res. 17(Suppl 2), N68–N74 (2002)
3. N. Yu, P.T. Donnan, R.W. Flynn, M.J. Murphy, D. Smith, A. Rudman, G.P. Leese, Increased mortality and morbidity in mild primary hyperparathyroid patients. The parathyroid epidemiology and audit research study (PEARS). Clin. Endocrinol. 73, 30–34 (2010)
4. E. Osto, F. Fallo, M.R. Pelizzo, A. Maddalozzo, N. Sorgato, F. Corbetti, R. Montisci, G. Famoso, R. Bellu, T.F. Lüscher, S. Iliceto, F. Tona, Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation 126, 1031–1039 (2012)
5. M.D. Walker, S.J. Silverberg, Cardiovascular aspects of primary hyperparathyroidism. J. Endocrinol. Invest. 31, 925–931 (2008)
6. F. Tassone, M. Procopio, L. Gianotti, G. Visconti, A. Pia, M. Terzolo, G. Borretta, Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet. Med. 26, 968–973 (2009)
7. E. Hagstrom, E. Lundgren, H. Lithell, L. Berglund, S. Ljunghall, P. Hellman, J. Rastad, Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin. Endocrinol. 56, 253–260 (2002)
8. A. Bergenfelz, A. Bladström, M. Their, E. Nordenström, S. Valdemarsson, J. Westerdahl, Serum levels of uric acid and diabetes mellitus influence survival after surgery for primary hyperparathyroidism: a prospective cohort study. World J. Surg. 31, 1393–1400 (2007)
9. M.J. Bolland, A.B. Grey, G.D. Gamble, I.R. Reid, Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 1525–1530 (2005)
10. E. Delfini, L. Petramala, C. Caliumi, D. Cotesta, G. De Toma, G. Cavallaro, G. Panzironi, D. Diacinti, S. Minisola, E. D’ Erasmo, G.F. Mazzuoli, C. Letizia, Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 56, 30–36 (2007)
11. R. Luboshitzky, Y. Chertok-Schaham, I. Lavi, A. Ishay, Cardiovascular risk factors in primary hyperparathyroidism. J. Endocrinol. Invest. 32, 317–321 (2009)
12. D. Han, S. Trooskin, X. Wang, Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J. Endocrinol. Invest. (2011). doi:10.3275/7861
13. E. Hagström, P. Hellman, T.E., E. Ingelsson, L. Berglund, J. Sundström, H. Melhus, C. Held, L. Lind, K. Michaëlsson, J. Arnlöv. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 119, 2765–2771 (2009)
14. J.L. Anderson, R.C. Vanwoerkom, B.D. Horne, T.L. Bair, H.T. May, D.L. Lappé, J.B. Muhlestein, Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am. Heart J. 162, 331–339 (2011)
15. W.D. Fraser, Hyperparathyroidism. Lancet 374, 145–158 (2009)
16. J.P. Bilezikian, A.A. Khan, J.T. Potts Jr, Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. J. Clin. Endocrinol. Metab. 94, 335–339 (2009)
17. F. Tassone, L. Gianotti, C. Baffoni, F. Cesario, G. Magro, M. Pellegrino, I. Emmolo, M. Maccario, G. Borretta, Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism. J. Endocrinol. Invest. (2011). doi:10.3275/8192
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002)
19. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)
20. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia, Report of a WHO/IDF consultation (2006) (http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf accessed in data 22/08/2012)
21. G. Mansia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A.M. Heagerty, S.E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R.E. Schmieder, H.A. Struijker Boudier, A. Zanchetti, European Society of Hypertension; European Society of Cardiology. ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Blood. Press 16, 135–232 (2007)
22. J.B. Meigs, P.W.F. Wilson, D.M. Nathan, R.B. D’Agostino Sr, K. Williams, S.M. Haffner, Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies. Diabetes 52, 2160–2167 (2003)
23. T. Apridonidze, P.A. Essah, M.J. Iuorno, J.E. Nestler, Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 1929–1935 (2005)
24. D.A. De Luis, G.D. Soto, R. Conde, O. Izaola, B. de la Fuente, Relation of leptin and adiponectin with cardiovascular risk factors, intact parathormone, and vitamin D levels in patients with primary hyperparathyroidism. J. Clin. Lab. Anal. 26, 398–402 (2012). doi:10.1002/jcla.21541
25. P. Luigi, F.M. Chiara, Z. Laura, M. Cristiano, C. Giuseppina, C. Luciano, P. Giuseppe, C. Sabrina, S. Susanna, C. Antonio, C. Giuseppe, T. Giorgio, L. de Claudio, Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results. Int. J. Endocrinol. (2012). doi:10.1155/2012/408295
26. E. Hagstrom, E. Lundgren, J. Rastad, P. Hellman, Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur. J. Endocrinol. 155, 33–39 (2006)
27. K.M. Tordjman, M. Yaron, E. Izkhakov, E. Osher, G. Shenkerman, Y. Marcus-Perlman, N. Stern, Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur. J. Endocrinol. 162, 925–933 (2010)
28. D.P. Macfarlane, N. Yu, P.T. Donnan, G.P. Leese, Should ‘mild primary hyperparathyroidism’ be reclassified as ‘insidious’: is it time to reconsider? Clin. Endocrinol. 75, 730–737 (2011). doi:10.1111/j.1365-2265.2011.04201.x
29. J. Bollerslev, T. Rosen, C.L. Mollerup, J. Nordenström, M. Baranowski, C. Franco, Y. Pernow, G.A. Isaksen, K. Godang, T. Ueland, S. Jansson, Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2255–2261 (2009)
30. A.A. Khaleeli, J.N. Johnson, W.H. Taylor, Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab. Res. Rev. 23, 43–48 (2007)
31. M.R. Rubin, S.J. Silverberg, Glucose intolerance and primary hyperparathyroidism: an unresolved relationship. Endocrine 42, 231–233 (2012)
32. A. Kautzky-Willer, G. Pacini, B. Niederle, G. Schernthaner, R. Prager, Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery. Clin. Endocrinol. 37, 147–155 (1992)
33. S. Kumar, A.O. Olukoga, C. Gordon, E.B. Mawer, M. France, J.P. Hosker, M. Davies, A.J. Boulton, Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin. Endocrinol. 40, 47–53 (1994)
34. F. Tassone, M. Maccario, L. Gianotti, C. Baffoni, M. Pellegrino, S. Cassibba, F. Cesario, G. Magro, G. Borretta, Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine (2013). doi:10.1007/s12020-013-0059-z
35. I. Cakir, K. Unluhizarci, F. Tanriverdi, G. Elbuken, Z. Karaca, F. Kelestimur, Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 42, 419–422 (2012)
36. T. Yamaguchi, I. Kanazawa, S. Takaoka, T. Sugimoto, Serum calcium is positively correlated with fasting plasma glucose and insulin resistance, independent of parathyroid hormone, in male patients with type 2 diabetes mellitus. Metabolism 60, 1334–1339 (2011)
37. P.J. Buizert, N.M. van Schoor, S. Simsek, P. Lips, A.C. Heijboer, M. den Heijer, D.J. Deeg, E.M. Eekhoff, PTH: a new target in arteriosclerosis? J Clin Endocrinol Metab (2013). doi:10.1210/jc.2013-1621
38. T. Skaaby, L.L. Husemoen, C. Pisinger, T. Jørgensen, B.H. Thuesen, M. Fenger, A. Linneberg, Vitamin D status and incident cardiovascular disease and all-cause mortality: a general population study. Endocrine 43, 618–625 (2013)